Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 28, 2007

Primary Completion Date

November 24, 2010

Study Completion Date

August 1, 2012

Conditions
Advanced Cancer
Interventions
DRUG

RDEA119

In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.

Trial Locations (3)

14263

Roswell Park Cancer, Buffalo

80045

UCHSC, Aurora

85258

TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY